Latest news
Finance, mergers and appointments
Vertex Completes acquisition of Crinetics Pharmaceuticals and announces expansion of executive leadership team
Vertex Pharmaceuticals has successfully acquired Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for endocrine diseases. Vertex also...
Drug Discovery & Development
Takeda Receives US FDA approval of Mimrylo (rusfertide), marking a potential shift in the treatment paradigm for polycythaemia vera
Takeda has announced US FDA approval of the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythaemia...
Drug Discovery & Development
uniQure announces submission of biologics license application for ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease
UniQure has applied for a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an...
Clinical Trials Insights
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
Novartis has announced positive topline results from its phase 3 trials of remibrutinib in relapsing multiple sclerosis.
Remibrutinib, a highly selective and potent oral Bruton’s...
Drug Discovery & Development
FDA approves Imaavy (nipocalimab-aahu) as first-ever treatment for warm autoimmune haemolytic anaemia (wAIHA), representing a landmark advancement for patients
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA) – a...
Clinical Trials Insights
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
GSK presented positive phase 2 data for its mRNA seasonal influenza (flu) vaccine candidate at the Options XIII Conference for the Control of Influenza.
GSK’s...
Drug Discovery & Development
FDA approves Gilead’s Bixlenvo, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens
The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for...
Finance, mergers and appointments
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Eli Lilly and Merida Biosciences, have announced a definitive agreement for Lilly to acquire Merida.
Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a...
Clinical Trials Insights
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
Eli Lilly and Company (NYSE: LLY) has announced 52-week results from Together-PsO and Together-PsA, two novel open-label phase 3b clinical trials evaluating the concomitant use of...
Clinical Trials Insights
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
BridgeBio Pharma has presented new analyses from the phase 3 study of Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including the cardiac magnetic resonance...
Drug Discovery & Development
European Commission approves Jascayd, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
The European Commission (EC) has granted marketing authorisation for Boehringer Ingelheim’s Jascayd (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and...
Beam Therapeutics has appointed Eric Foster as chief commercial officer.
Mr Foster will lead Beam’s commercial organisation and strategy as the company advances multiple product...
Drug Delivery and Supply Chain
AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer
AstraZeneca has started an exclusive licencing agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung...
Drug Discovery & Development
Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients...
Clinical Trials Insights
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Amgen and AstraZeneca have announced positive top-line results from the phase 3 trial of Tezspire (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE).
Tezspire demonstrated statistically...
Drug Discovery & Development
Abbott receives FDA authorisation for world’s first dual glucose-ketone sensing technology for people with diabetes
The US Food and Drug Administration (FDA) has granted authorisation to Abbott’s Libre Duo 10 Day system, said to be the world's first dual...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
